Related Experiment Video
Updated: Jun 14, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Isolation and Characterization of a Novel Phage SaGU1 that Infects Staphylococcus aureus Clinical Isolates from
Yuzuki Shimamori1,2, Ajeng K Pramono3, Tomoe Kitao1
1Department of Microbiology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Abstract:
The bacterium Staphylococcus aureus, which colonizes healthy human skin, may cause diseases, such as atopic dermatitis (AD). Treatment for such AD cases involves antibiotic use; however, alternate treatments are preferred owing to the development of antimicrobial resistance. This study aimed to characterize the novel bacteriophage SaGU1 as a potential agent for phage therapy to treat S. aureus infections. SaGU1 that infects S. aureus strains previously isolated from the skin of patients with AD was screened from sewage samples in Gifu, Japan. Its genome was sequenced and analyzed using bioinformatics tools, and the morphology, lytic activity, stability, and host range of the phage were determined. The SaGU1 genome was 140,909 bp with an average GC content of 30.2%. The viral chromosome contained 225 putative protein-coding genes and four tRNA genes, carrying neither toxic nor antibiotic resistance genes. Electron microscopy analysis revealed that SaGU1 belongs to the Myoviridae family. Stability tests showed that SaGU1 was heat-stable under physiological and acidic conditions. Host range testing revealed that SaGU1 can infect a broad range of S. aureus clinical isolates present on the skin of AD patients, whereas it did not kill strains of Staphylococcus epidermidis, which are symbiotic resident bacteria on human skin. Hence, our data suggest that SaGU1 is a potential candidate for developing a phage therapy to treat AD caused by pathogenic S. aureus.
Insights
A novel bacteriophage, SaGU1, shows promise for treating Staphylococcus aureus infections in atopic dermatitis (AD). This phage effectively targets S. aureus strains from AD skin, offering a potential alternative to antibiotics.
Area of Science:
- Microbiology
- Virology
- Dermatology
Background:
- Staphylococcus aureus is a common skin colonizer that can cause atopic dermatitis (AD).
- Antibiotic resistance necessitates alternative treatments for S. aureus infections.
- Phage therapy presents a promising alternative to conventional antibiotic treatments.
Purpose of the Study:
- To characterize the bacteriophage SaGU1 as a potential therapeutic agent against S. aureus.
- To evaluate SaGU1's efficacy in targeting S. aureus strains from atopic dermatitis patients.
- To assess the safety and host range of SaGU1 for potential phage therapy applications.
Main Methods:
- Screening of bacteriophages from sewage samples.
- Genomic sequencing and bioinformatics analysis of bacteriophage SaGU1.
- Electron microscopy for morphology determination.
- Lytic activity, stability, and host range assays.
Main Results:
- SaGU1 possesses a 140,909 bp genome with 225 protein-coding genes and no toxic or antibiotic resistance genes.
- Electron microscopy identified SaGU1 as belonging to the Myoviridae family.
- SaGU1 demonstrated stability under physiological and acidic conditions.
- SaGU1 exhibited broad-spectrum lytic activity against S. aureus clinical isolates from AD patients, sparing Staphylococcus epidermidis.
Conclusions:
- Bacteriophage SaGU1 is a heat-stableMyoviridae phage with a broad host range against S. aureus relevant to atopic dermatitis.
- SaGU1 lacks undesirable genes, indicating its safety for therapeutic use.
- SaGU1 represents a promising candidate for developing phage therapy against S. aureus-associated atopic dermatitis.
Related Concept Videos
Lytic Cycle of Bacteriophages
DNA Bacteriophages
The Skin Microbiota
Staphylococcal Skin Infections
Clinical Significance of Antibiotic Resistance

